BlackRock
KRRO icon

BlackRock’s Korro Bio KRRO Stock Holding History

BlackRock’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.21M Buy
460,006
+2,607
+0.6% +$28.7K ﹤0.01% 3813
2025
Q4 		$3.66M Buy
457,399
+10,701
+2% +$250K ﹤0.01% 3943
2025
Q3 		$21.4M Sell
446,698
-15,191
-3% -$337K ﹤0.01% 3057
2025
Q2 		$5.77M Buy
461,889
+20,459
+5% +$295K ﹤0.01% 3703
2025
Q1 		$7.69M Sell
441,430
-11,019
-2% -$327K ﹤0.01% 3453
2024
Q4 		$17.2M Buy
452,449
+2,499
+0.6% +$128K ﹤0.01% 3137
2024
Q3 		$15M Buy
449,950
+43,569
+11% +$1.83M ﹤0.01% 3205
2024
Q2 		$13.8M Buy
406,381
+325,760
+404% +$18M ﹤0.01% 3196
2024
Q1 		$7.26M Sell
80,621
-5,007
-6% -$273K ﹤0.01% 3519
2023
Q4 		$4.1M Buy
85,628
+62,234
+266% +$2.05M ﹤0.01% 3762
2023
Q3 		$433K Sell
23,394
-1,088
-4% -$27.3K ﹤0.01% 4464
2023
Q2 		$424K Sell
24,482
-1,496
-6% -$29K ﹤0.01% 4528
2023
Q1 		$653K Sell
25,978
-2,420
-9% -$276K ﹤0.01% 4467
2022
Q4 		$5.47M Sell
28,398
-5,577
-16% -$574K ﹤0.01% 3682
2022
Q3 		$3.04M Sell
33,975
-771
-2% -$78.3K ﹤0.01% 3977
2022
Q2 		$2.61M Sell
34,746
-31,290
-47% -$2.11M ﹤0.01% 4130
2022
Q1 		$7M Buy
66,036
+5,136
+8% +$981K ﹤0.01% 3775
2021
Q4 		$15.6M Sell
60,900
-2,937
-5% -$893K ﹤0.01% 3419
2021
Q3 		$22.5M Buy
63,837
+2,422
+4% +$953K ﹤0.01% 3199
2021
Q2 		$30.6M Buy
61,415
+10,033
+20% +$4.9M ﹤0.01% 3043
2021
Q1 		$24.4M Sell
51,382
-55
-0.1% -$107K ﹤0.01% 3079
2020
Q4 		$90.7M Buy
51,437
+19,777
+62% +$26.1M ﹤0.01% 2141
2020
Q3 		$30.4M Sell
31,660
-419
-1% -$450K ﹤0.01% 2611
2020
Q2 		$37.3M Buy
32,079
+25,142
+362% +$22.7M ﹤0.01% 2419
2020
Q1 		$6.18M Sell
6,937
-2,636
-28% -$2.85M ﹤0.01% 3249
2019
Q4 		$8.39M Buy
+9,573
New +$7.45M ﹤0.01% 3330

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock's KRRO Position: Q1 2026 in Review

BlackRock increased its Korro Bio (KRRO) stake by 0.57% in Q1 2026, buying an estimated $28.7K and bringing the position to 460,006 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

BlackRock first reported a position in KRRO in Q4 2019 and has held it in 26 quarters since. The position peaked at $90.7M in Q4 2020. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

  • BlackRock held 460,006 shares of Korro Bio worth $5.21M as of Q1 2026.
  • BlackRock bought 2,607 Korro Bio shares in Q1 2026, an estimated $28.7K.
  • Korro Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3813 holding.
  • BlackRock first reported a position in Korro Bio in Q4 2019 and has held it in 26 quarters since.
  • BlackRock's Korro Bio position peaked at $90.7M in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.